About the Infographic
- A review of the approved PARP inhibitors showcased at ESMO 2022
- The progression of ATR inhibitors towards a regulatory approval
- DDR-relevant drug mechanisms of action
Find out more
This insight and data is part of the subscription to Beacon DDR.
Speak with our Team
Our dedicated Sales and Research teams can help you with questions by showing you how this insight and data is collated on Beacon
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements